Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration.

J Neurosurg 110(1):58-63 (2009) PMID 18847340

The calcium antagonist nimodipine has been shown to reduce the incidence of ischemic complications following aneurysmal subarachnoid hemorrhage (SAH). Although most randomized studies have been focused on the effect of the peroral administration of nimodipine, intravenous infusion is an alternative and the preferred mode of treatment in many centers. It is unknown whether the route of administration is of any importance for the clinical efficacy of the drug.